facebook_pixel
Equity Strategy 15 July 2013
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
Regeneron Pharmaceuticals: Uptrend Has Started. Profit Potential: 12.39%

Regeneron Pharmaceuticals: Uptrend Has Started. Profit Potential: 12.39%

* Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and  commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders * The company offers EYLEA […]

FIND OUT MORE